Ensuring the Quality of Priority Medicines
Workshop

USAID’S LEADERSHIP IN THE GLOBAL FIGHT AGAINST NTDs

PENNY SMITH

USAID/WASHINGTON, DC

JULY 25, 2017
1.9 billion people in 122 countries require PC for at least 1 disease.
33% requires PC for 3 or more diseases.
31 COUNTRIES SUPPORTED BY USAID

REGIONAL
Colombia
Ecuador
Guatemala
Mexico
Venezuela
Brazil

Benin
Burkina Faso
Cameroon
Côte d’Ivoire
DR Congo
Ethiopia
Ghana
Guinea
Mali
Mozambique
Niger
Nigeria

Senegal
Sierra Leone
Tanzania
Togo
Uganda

Bangladesh
Cambodia
Indonesia
Laos
Nepal
Philippines
Vietnam
## WHO & USAID 2020 TARGETS

<table>
<thead>
<tr>
<th>DISEASE</th>
<th>WHO</th>
<th>USAID</th>
</tr>
</thead>
<tbody>
<tr>
<td>LYMPHATIC FILARIASIS</td>
<td>Eliminate as a public health problem</td>
<td>Eliminate as a public health problem</td>
</tr>
<tr>
<td>TRACHOMA</td>
<td>Eliminate as a public health problem</td>
<td>Eliminate as a public health problem</td>
</tr>
<tr>
<td>ONCHOCERCIASIS</td>
<td>Eliminate in:</td>
<td>Eliminate in:</td>
</tr>
<tr>
<td></td>
<td>- Americas</td>
<td>- Americas</td>
</tr>
<tr>
<td></td>
<td>- Select countries in Africa</td>
<td>- Select countries in Africa</td>
</tr>
<tr>
<td></td>
<td>- Yemen</td>
<td></td>
</tr>
<tr>
<td>SOIL-TRANSMITTED HELMINTHIASIS</td>
<td>Reach 75% coverage: 100% endemic countries</td>
<td>Reach 75% coverage: 100% supported countries</td>
</tr>
<tr>
<td>SCHISTOSOMIASIS</td>
<td>Eliminate from the EMRO, Mekong River basin, AMRO, WPRO, and some countries in AFRO</td>
<td>Reach 75% coverage in 100% supported countries</td>
</tr>
</tbody>
</table>
USAID’s CORE ACTIVITIES

• Mapping for targeted diseases
• Integrated Mass Drug Administration for Elimination and Control diseases
• Disease Specific Assessments
• Drug Quality and Supply Chain Management
What the past 10 years have achieved
NTD PROGRAM KEY ACHIEVEMENTS

**2016**
- Supporting 31 countries
- $4.5 billion donated drugs leveraged
- 386.6 million NTD treatments
- 191 million individuals treated
- 1,074 disease specific assessments
- 78 districts mapped for disease
- 1,101,910 people trained
  - (712,779 drug distributors)

**TO DATE**
- Supported 33 countries
- $15.7 billion donated drugs leveraged
- >2 billion NTD treatments
- 936 million individuals treated
- 3,412 disease specific assessments
- 2,648 districts mapped for disease
- 478,000 people trained (annual average)
To date: 2 billion treatments to over 936 million people
VALUE FOR MONEY

% of Population No Longer Requiring Treatment

**Lymphatic Filariasis**
- 59% of Population
- 198.4 million people
- 615 districts

**Trachoma**
- 60% of Population
- 83.7 million people
- 323 districts

**Persons still living in areas at risk**
- 41%

**Persons no longer at risk (living in areas where criteria for stopping MDA achieved)**
- 59%

**Persons living in districts where criteria for stopping MDA have been achieved**
- 2011: 7.7 million
- 2012: 32 million
- 2013: 52.4 million
- 2014: 92.4 million
- 2015: 140.5 million
- 2016: 198.4 million

**Lymphatic Filariasis**
- 282 million people
- 1,253 districts

**Trachoma**
- 124.5 million people
- 882 districts
ANNUAL VALUE OF DONATED DRUGS DELIVERED TO USAID-SUPPORTED COUNTRIES

Value of donated drugs (Millions)

USAID NTD Funding

$15.7 billion in drugs have been donated to countries supported by USAID


US $ in Millions

$- $500 $1,000 $1,500 $2,000 $2,500 $3,000 $3,500 $4,000 $4,500 $5,000

$404 $507 $577 $686 $949 $1,080 $2,500 $2,177 $2,249 $4,595


$15 $15 $25 $65 $77 $89 $85 $100 $100 $100
### USAID Priority Diseases

<table>
<thead>
<tr>
<th>Disease</th>
<th>WHO 2020 Goal</th>
<th>Number USAID supported countries</th>
<th>Number USAID supported countries on track to meet WHO 2020 goal</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lymphatic Filariasis</td>
<td>Elimination</td>
<td>24</td>
<td>15</td>
</tr>
<tr>
<td>Trachoma</td>
<td>Elimination</td>
<td>19</td>
<td>16</td>
</tr>
<tr>
<td>Onchocerciasis Americas by 2018</td>
<td>Elimination</td>
<td>6</td>
<td>6</td>
</tr>
</tbody>
</table>

### Diseases Benefitting from Integration

<table>
<thead>
<tr>
<th>Disease</th>
<th>WHO 2020 Goal</th>
<th>Number USAID supported countries</th>
<th>Number USAID supported countries on track to meet WHO 2020 goal</th>
</tr>
</thead>
<tbody>
<tr>
<td>Onchocerciasis Africa</td>
<td>Control Elimination where possible*</td>
<td>15</td>
<td>13 Control (# Elimination/TBD)</td>
</tr>
<tr>
<td>Soil Transmitted Helminths</td>
<td>Control</td>
<td>26</td>
<td>19 (100% geographical coverage)</td>
</tr>
<tr>
<td>Schistosomiasis</td>
<td>Control</td>
<td>19</td>
<td>11 (100% geographical coverage)</td>
</tr>
</tbody>
</table>

*New WHO guidelines released 12/2015 which will be used to determine countries on-track for elimination.*
Expanding the Landscape for Long-Term Program Sustainability
Creating Platforms for Delivery

• Creating sustainable platforms for Onchocerciasis, Schistosomiasis and Soil-transmitted Helminths post-elimination of LF
  – Each country sets their own goals and platforms
  – Incorporate audiences not reached with donated drugs
• Creating new markets for drugs to target them, especially for audiences not eligible for donation
• Supporting WHO on updating treatment and assessment guidelines to ensure each audience receives the right amount of drug at the right frequency, and that health districts are assessed for progress.
Global donation programs largely target SAC, but don’t reach other crucial audiences essential for sustainable disease control.

Pharma donations have been extraordinarily generous, but are unlikely to extend indefinitely; new manufacturers are needed to fill future gaps.

Governments will be held accountable by WHO for reaching their Sustainable Development Goals to “ensuring healthy lives and promote wellbeing for all”.

Potential Targets for Prequalified drugs

<table>
<thead>
<tr>
<th>Target Category</th>
<th>Target Group</th>
<th>Status</th>
</tr>
</thead>
<tbody>
<tr>
<td>High-risk Adults (HRA)</td>
<td></td>
<td>Often excluded from donation programs</td>
</tr>
<tr>
<td>School-aged Children (SAC) 5-14 years</td>
<td></td>
<td>Primary target audience for donation but not 100% at global scale</td>
</tr>
<tr>
<td>Pre-School aged Children (PSAC)</td>
<td></td>
<td>Often excluded from donation programs</td>
</tr>
</tbody>
</table>
Identifying and Tapping Potential Markets for High Quality Drugs

- Donor governments
- Private foundations
- Non-governmental partners and Faith-based organizations
  - NTD programs as well as ancillary markets (Nutrition, Child Survival programs)
  - Partners buy and donate drugs to meet in-kind contribution requirements
- Host-country governments self-financing

As more donors come into the sphere, the requirements for higher quality drugs increase
Explore the NTD Donor Landscape

NTD Donor Landscape 2016

The donor landscape has been initiated by the U.S. Agency for International Development (USAID) and the U.K. Department for International Development (DFID), both supporters of the World Health Organization’s 2020 goals to control or eliminate neglected tropical diseases (NTDs). This document was developed in response to the growing number of requests from the global NTD community to better understand the focus of donor contributions. The 2012 London Declaration on NTDs, a global policy milestone, underscores the growing global momentum to accelerate progress toward the 2020 goals.

Download a copy of the NTD Donor Landscape 2016 [PDF, 28.3MB], or read it online:

https://www.neglecteddiseases.gov/resources/newsroom/donor-landscape